摘要
目的探讨表皮生长因子受体（EGFR）基因突变在晚期非小细胞肺癌（NSCLC）二线治疗中的指导意义。方法对2005年12月至2009年12月住我院的139例既往至少接受过1次含铂化疗且最近1次化疗后肿瘤进展或复发的NSCLC的病理组织行EGFR基因检测，根据检测的结果把患者分为EGFR突变型口服吉非替尼组（31例）和EGFR野生型口服吉非替尼组（50例）及EGFR野生型口服吉非替尼组（50例）。对3组患者进行临床特征、病理、疗效、生存期、体力状况评分（PS）、毒副反应及生活质量的分析。结果女性、腺癌、非吸烟者的EGFR突变率高于对应组；突变型吉非替尼组、野生型吉非替尼组（62．0％，31例）和野生型多烯紫杉醇组中位无进展生存期（分别为2．8、2．0和2．5个月）、中位生存时间（分别为8．9、7．1和7．8个月）比较，差异有统计学意义（H值分别为11．198、16．991，均P〈0．01）。突变型吉非替尼组、野生型吉非替尼组PS评分的变化分别为96．8％（30例）和62．0％（31例），差异有统计学意义（y。一12．583，P〈0．01）。野生型吉非替尼组（62．0％，31例）和野生型多烯紫杉醇组（66．0％，33例）化疗PS评分变化比较，差异无统计学意义（x2=0．878，P〉0．05）。结论表皮生长因子受体基因突变可作为指导晚期NSCLC二线治疗的重要指标。
Objective To explore the effect of gene mutations of epidermal growth factor receptor （EGFR） on targeting therapy of advanced non-small ceil lung cancer （NSCLC）. Methods The 139 hospitalized patients who had been treated at least once with platinum-based chemotherapy and had tumor progression or recurrence after the last chemotherapy between December 2005 and December 2009, underwent EGFR gene test extracted from the pathological tissues. Based on the results of the test, the patients were divided into three groups： EGFR mutation per os （p.o.） Gefitinib ＂（MpG） group, wild-type EGFR per os （p. o. ） Gefitinib （WpG） group and wild-type EGFR post-docetaxel chemotherapy （WpD） group. Clinical characteristics, pathology, treatment efficacy, survival time, performance status （PS） score, adverse reaction and quality of life of patients in the three groups were assessed. Results The EGFR mutation rate were higher in female, patients with adenoearcinoma and non-smokers than in male, smokers and those without adenoearcinoma. There were significant differences in median progression-free survival and median survival time among the three groups, which were 2.8 and 8.9 months in MpG group, 2.0 and 7.1 months in WpG group, 2.5 and 7.8 months inWpDgroup（H=11.198, 16.991,all P〈0.01）. The changes of PS score were significantly different between MpG group and WpG group （96.8% vs. 62.0%, Z2 = 12. 583 ,P〈 0.01）. However, there was no difference in changes of PS score between WpG group and WpD group （62.0% vs. 66.0 % , x2 = 0. 878, P〉0.05）. Conclusions The gene mutation of epidermal growth factor receptor may be served as an important indicator of advanced non-small cell cancer therapy.
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2011年第8期657-660,共4页
Chinese Journal of Geriatrics
基金
基金项目：厦门市科技计划社会发展项目（3502220074021）
关键词
癌
非小细胞肺
受体
表皮生长因子
DNA突变分析
Carcinoma, non-small-cell lung
Receptor, epidermal growth factor
DNA mutational analysis
